Pharmaceutical Technology, August 2010 Issue (PDF)

Cambridge Healthcare Innovations says its dry powder inhaler engine, Quattrii, can deliver large volumes of biologic and mRNA molecules in a single inhalation.

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.

The department’s newly announced partnerships were part of a weeklong visit that included discussions held at BIO 2025.